Evaluation of the combination of regorafenib + avelumab in patients with non-small cell lung cancer without oncogenic addiction: The phase II REGOMUNE study. This is an ASCO Meeting Abstract from the ...

A phase 1 dose escalation and dose expansion study for LNCB74, a B7-H4 targeted antibody drug conjugate, as monotherapy in participants with advanced solid tumors. This is an ASCO Meeting Abstract ...

Dana-Farber Cancer Institute investigators launch a first-of-its kind study to use a novel blood test to identify people who ...

In a bold step toward equitable cancer care, Gene Solutions introduces SPOT-MAS Lung, a next-generation blood-based test ...

Tens of thousands of patients with lung and breast cancer are to benefit from a “revolutionary” blood test on the NHS across England which can speed up access to targeted therapy. The new ‘liquid ...

The study found that cfDNA levels increase significantly ... and treatment response in cancers such as lung, breast, and colorectal cancer. Colorectal cancer is one of the most common cancers ...

Galleri is a blood test that aims to detect over 50 types of cancer early. It analyzes cell-free DNA (cfDNA) and methylation patterns to identify potential cancer signals. The test is intended for ...

Prenatal cell-free DNA (cfDNA) screening during ... pancreatic, lung, kidney, bone, and adrenal gland cancers. Of the 52 with cancer, 29 (55.8 percent) had no symptoms of their disease.

Electronic nose breath analysis achieved 80-92% accuracy for detecting lung cancer in patients with suspicious findings. Detection accuracy remained consistent across tumor characteristics ...

Cell-free DNA (cfDNA) sequence analysis to screen for fetal aneuploidy can incidentally detect maternal cancer. Additional data are needed to identify DNA-sequencing patterns and other biomarkers ...